Latest Breaking News On - Sponsored leveli american depositary receipt - Page 21 : comparemela.com

Ipsen: ASCO 2022: New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer

COSMIC-021 Phase Ib study is evaluating Cabometyx (cabozantinib) in combination with atezolizumab in advanced solid tumors, including non-small cell lung cancer New analyses from pivotal Phase

France generalUnited statesUnited kingdomHong kongNew zealandWorld health organizationAl qahirahSouth koreaDominican republicSaudi arabiaGreat britainRussian federationMon junHoward mayerIpsen euronextHead of research

IPSEN: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to Be Approved at the Combined Shareholders Meeting on 24 May 2022 (17th Resolution)

Regulatory News: IPSEN (Paris:IPN) (OTC Pink:IPSEY): In accordance with the provisions of Article L. 22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of

France generalUnited kingdomUnited statesGeorges gorseGwenan whiteIoana piscociuGlobal communicationsPublic affairsEuropean parliamentCompany or groupRegulatory newsFrench commercial codeEuropean regulationDelegated regulationGeneral regulationFrench autorit

Combined Shareholders Meeting of Ipsen S A Held on 24 May 2022

ALL THE RESOLUTIONS SUBMITTED TO THE SHAREHOLDERS' VOTE HAVE BEEN APPROVED. Regulatory News: The Combined Shareholders' Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY), was held today at the

France generalUnited statesUnited kingdomAymeric leIpsen sa euronextGroup executive leadership teamCombined shareholder meetingDes artsExecutive leadershipShareholder meetingPricewaterhousecoopers auditDeloitte associMrs karenChief executive officerGroup chief financial officerRare disease

Ipsen: European Commission Approves Cabometyx as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 This milestone

Israel generalFrance generalUnited statesUnited kingdomHong kongNew zealandSouth koreaComunidad autonoma de catalunaDominican republicSaudi arabiaGreat britainRussian federationJaume capdevilaGemma roperIpsen euronextHebron university hospital

Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesUnited kingdomHong kongNew zealandSouth koreaIsrael generalComunidad autonoma de catalunaDominican republicSaudi arabiaGreat britainRussian federationJaume capdevilaSteven hildemannGemma roperIpsen euronext